Making conclusions from the DCVax-L P3 trial is no valid because of the massive confounding of the OS data. Any of the trials would have better outcomes if you had done repeated doses of the treatment medication. But well-controlled trials don't do extra doses that would biased the trial. FDA frowns highly on post hoc trial changes like NWBO has just done. So comparing NWBO trial to any other trial is inappropriate because of the confounded OS data.
Market Data 
Markets 
AI
